Skip to main content

Drug Interactions between momelotinib and Nicotrol Inhaler

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nicotine momelotinib

Applies to: Nicotrol Inhaler (nicotine) and momelotinib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of momelotinib may increase the plasma concentrations and effects of drugs that are substrates of CYP450 2B6. The proposed mechanism, based on in vitro data, is decreased drug clearance due to momelotinib-mediated inhibition of the CYP450 2B6 isoenzyme. However, clinical data are not available.

MANAGEMENT: Caution is advised if the momelotinib is administered with sensitive substrates of CYP450 2B6. Patients should be monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever momelotinib is added to or withdrawn from therapy with these drugs. Individual product labeling for the coadministered drug may also be consulted for specific guidance.

Drug and food/lifestyle interactions

Minor

nicotine food/lifestyle

Applies to: Nicotrol Inhaler (nicotine)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer